RESUMEN
OBJECTIVES: In a sample of patients with cancer (n=1145) who were assessed during the height of the COVID-19 pandemic, latent profile analysis was used to identify subgroups of patients with distinct stress profiles and to evaluate for differences in demographic and clinical characteristics and symptom severity scores among these subgroups. METHODS: Patients completed measures of cancer-specific and COVID-19 stress, global stress, social isolation, loneliness, depression, state and trait anxiety, morning and evening fatigue, morning and evening energy, sleep disturbance, cognitive function, and pain. Latent profile analysis was used to identify subgroups of patients with distinct stress profiles. Differences among the subgroups in study measures were evaluated using parametric and non-parametric tests. RESULTS: Using clinically meaningful cut-off scores for the stress measures, four distinct stress profiles were identified (ie, none class (51.3%); low stress and moderate loneliness class (24.4%), high stress and moderate loneliness class (14.0%), and very high stress and moderately high loneliness class (high, 10.3%)). Risk factors associated with membership in the high class included: younger age, lower annual household income, lower functional status and higher comorbidity burden. The two worst stress profiles reported clinically meaningful levels of all of the common symptoms associated with cancer and its treatments. CONCLUSION: Findings from this study, obtained prior to the availability of COVID-19 vaccines and anti-viral medications, provide important 'benchmark data' to evaluate for changes in stress and symptom burden in patients with cancer in the postvaccine era and in patients with long COVID-19.
Asunto(s)
COVID-19 , Neoplasias , Humanos , COVID-19/epidemiología , Carga Sintomática , Vacunas contra la COVID-19 , Pandemias , Síndrome Post Agudo de COVID-19 , Neoplasias/complicaciones , Neoplasias/epidemiología , Neoplasias/diagnóstico , Fatiga/epidemiología , Fatiga/etiologíaRESUMEN
La síntesis de análogos de hormona liberadora de gonadotropinas (GnRH) ha permitido manipular, de manera segura y eficaz, el estado hormonal de las mujeres con endometriosis y crear un estado hipoestrogénico reversible, que ocasiona reducción en los implantes endometriósicos y mejoría de la sintomatología, sin los efectos adversos que se observan con el danazol